Display options
Cite
Kobayashi M, Suzuki F, Akuta N, et al. Correlation of YMDD mutation and breakthrough hepatitis with hepatitis B virus DNA and serum ALT during lamivudine treatment. Hepatol Res. 2009;40(2):125-34doi: 10.1111/j.1872-034X.2009.00565.x.
Kobayashi, M., Suzuki, F., Akuta, N., Yatsuji, H., Hosaka, T., Sezaki, H., Kobayashi, M., Kawamura, Y., Suzuki, Y., Arase, Y., Ikeda, K., Mineta, R., Iwasaki, S., Watahiki, S., & Kumada, H. (2010). Correlation of YMDD mutation and breakthrough hepatitis with hepatitis B virus DNA and serum ALT during lamivudine treatment. Hepatology research : the official journal of the Japan Society of Hepatology, 40(2), 125-34. https://doi.org/10.1111/j.1872-034X.2009.00565.x
Kobayashi, Mariko, et al. "Correlation of YMDD mutation and breakthrough hepatitis with hepatitis B virus DNA and serum ALT during lamivudine treatment." Hepatology research : the official journal of the Japan Society of Hepatology vol. 40,2 (2010): 125-34. doi: https://doi.org/10.1111/j.1872-034X.2009.00565.x
Kobayashi M, Suzuki F, Akuta N, Yatsuji H, Hosaka T, Sezaki H, Kobayashi M, Kawamura Y, Suzuki Y, Arase Y, Ikeda K, Mineta R, Iwasaki S, Watahiki S, Kumada H. Correlation of YMDD mutation and breakthrough hepatitis with hepatitis B virus DNA and serum ALT during lamivudine treatment. Hepatol Res. 2010 Feb;40(2):125-34. doi: 10.1111/j.1872-034X.2009.00565.x. Epub 2009 Sep 25. PMID: 19788696.
Copy Download .nbib Format: NLM
Share it on

Hepatol Res. 2010 Feb;40(2):125-34. doi: 10.1111/j.1872-034X.2009.00565.x. Epub 2009 Sep 25.

Correlation of YMDD mutation and breakthrough hepatitis with hepatitis B virus DNA and serum ALT during lamivudine treatment.

Hepatology research : the official journal of the Japan Society of Hepatology

Mariko Kobayashi, Fumitaka Suzuki, Norio Akuta, Hiromi Yatsuji, Tetsuya Hosaka, Hitomi Sezaki, Masahiro Kobayashi, Yusuke Kawamura, Yoshiyuki Suzuki, Yasuji Arase, Kenji Ikeda, Rie Mineta, Satomi Iwasaki, Sachiyo Watahiki, Hiromitsu Kumada

Affiliations

  1. Research Institute for Hepatology, Toranomon Hospital, Tokyo, Japan.

PMID: 19788696 DOI: 10.1111/j.1872-034X.2009.00565.x

Abstract

AIM: Continuous lamivudine treatment is associated with high frequency of drug resistance. We analyzed the incidence of tyrosine-methionine-aspartate-aspartate (YMDD) motif mutant and breakthrough hepatitis (BTH) in hepatitis B virus (HBV) DNA positive patients receiving lamivudine for > 1 year and correlated it with HBV DNA and alanine aminotransferase (ALT) levels to evaluate if these measurements can provide a practical option for monitoring patients in clinical practice and define early switch from lamivudine therapy.

METHODS: Of the 929 patients receiving lamivudine for > 1 year, 359 patients who maintained an ALT level of /= 3 years.

RESULTS: The incidence of YMDD motif in patients receiving lamivudine for < 3 years was 27% in patients with ALT

CONCLUSION: Correlation of ALT and HBV DNA levels with YMDD motif mutant and BTH indicates that these measurements can be used in clinical practice for deciding early switch from lamivudine to other suitable antiviral therapies.

Publication Types